Literature DB >> 15863010

New antitubulin derivatives in the combretastatin A4 series: synthesis and biological evaluation.

Christine Borrel1, Sylviane Thoret, Xavier Cachet, Daniel Guénard, François Tillequin, Michel Koch, Sylvie Michel.   

Abstract

Two series of combretastatin A4 derivatives (acrylamide=carboxamide and carbamate) were synthesized in order to improve the water solubility and stabilize the cis-configuration of the double bond. Their cytotoxic effects were evaluated against MCF-7, KB-3-1 and IGROV human cancer cell lines, as well as their inhibitory activity on tubulin polymerization. Results were compared to those of carboxamide 1, chosen as reference. Potent inhibitions were observed on both tests in the carboxamide series, particularly for compound 4d bearing a fluorine group in replacement of the 3-hydroxyl of CA4. In contrast, most of the carbamates were either inactive or displayed only moderate cytotoxicities. Interestingly, a submicromolar IC(50) was measured on MCF-7 cells for 6g, although this compound was totally devoid of antitubulin activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863010     DOI: 10.1016/j.bmc.2005.02.039

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Novel antimitotic agents related to tubuloclustin: synthesis and biological evaluation.

Authors:  Olga N Zefirova; Evgeniya V Nurieva; Birgit Wobith; Vladimir V Gogol; Nikolay A Zefirov; Andrei V Ogonkov; Dmitrii V Shishov; Nikolay S Zefirov; Sergei A Kuznetsov
Journal:  Mol Divers       Date:  2017-05-08       Impact factor: 2.943

2.  Synthesis and biochemical evaluation of triazole/tetrazole-containing sulfonamides against thrombin and related serine proteases.

Authors:  Rogelio Siles; Yuko Kawasaki; Patrick Ross; Ernesto Freire
Journal:  Bioorg Med Chem Lett       Date:  2011-07-14       Impact factor: 2.823

3.  Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Authors:  Patrick M Kelly; Niall O Keely; Sandra A Bright; Bassem Yassin; Gloria Ana; Darren Fayne; Daniela M Zisterer; Mary J Meegan
Journal:  Molecules       Date:  2017-08-31       Impact factor: 4.411

4.  Synthesis, biological evaluation, and modeling studies of 1,3-disubstituted cyclobutane-containing analogs of combretastatin A4.

Authors:  Andrii Malashchuk; Anton V Chernykh; Vasyl V Hurmach; Maxim O Platonov; Oleksandra Onopchenko; Sergey Zozulya; Constantin G Daniliuc; Alexey V Dobrydnev; Ivan S Kondratov; Yuriy S Moroz; Oleksandr O Grygorenko
Journal:  J Mol Struct       Date:  2020-05-10       Impact factor: 3.196

5.  Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.

Authors:  Niall O Keely; Miriam Carr; Bassem Yassin; Gloria Ana; David G Lloyd; Daniela Zisterer; Mary J Meegan
Journal:  Biomedicines       Date:  2016-07-20

6.  Design, synthesis and biological evaluation of a series of new resveratrol analogues as potential anti-cancer agents.

Authors:  Lifang Yang; Xuemei Qin; Hongcun Liu; Yanye Wei; Hailiang Zhu; Mingguo Jiang
Journal:  R Soc Open Sci       Date:  2019-09-04       Impact factor: 2.963

7.  Synthesis and antitumor activity of novel silibinin and 2,3-dehydrosilybin derivatives with carbamate groups.

Authors:  Qiuchan Wu; Jiang Zeng; Jinfu Dong
Journal:  Med Chem Res       Date:  2022-02-15       Impact factor: 1.965

8.  Novel resveratrol-based substrates for human hepatic, renal, and intestinal UDP-glucuronosyltransferases.

Authors:  Aleksandra K Greer; Nikhil R Madadi; Stacie M Bratton; Sarah D Eddy; Zofia Mazerska; Howard P Hendrickson; Peter A Crooks; Anna Radominska-Pandya
Journal:  Chem Res Toxicol       Date:  2014-03-11       Impact factor: 3.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.